Novartis India has posted a net profit growth of 26.5 per cent during the year ended March 2011 to Rs.146.67 crore from Rs.115.99 crore in the previous year. Its net sales went up by 13.6 per cent to Rs.708.64 crore from Rs.624.10 crore. Th board of directors has declared equity dividend of 200 per cent for the year 2010-11.
The pharmaceutical sales increased by 12 per cent to Rs.489.78 crore from Rs.437.30 crore and that of generics grew by 18.6 per cent to Rs.47.34 crore from Rs.39.91 crore. The sales of OTC products up by 17.3 per cent to Rs.100.86 crore from Rs.85.97 crore. The company's sales of animal health products increased by 16 per cent to Rs.70.66 crore from Rs.60.92 crore.
Its EBDITA increased by 21.5 per cent to Rs.221.57 crore from Rs.182.37 crore. Earnings per share worked out to Rs.45.90 as compared to Rs.36.29 in the last year. As against the equity capital of Rs.15.98 crore, its reserves and surplus touched to Rs.687.01 crore during the year 2010-11, a growth of 19 per cent over the previous year.